NASDAQ:ARVN

Arvinas - ARVN News Today

$26.34

-1.34 (-4.84%)

(As of 03/23/2023 12:00 AM ET)

Add

Compare

Today's Range: $26.17
▼
$28.49
50-Day Range: $26.34
▼
$37.26
52-Week Range: $26.17
▼
$75.39

Volume: 774,150 shs
Average Volume: 505,349 shs
Market Capitalization: $1.40 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.75

Institutional Ownership

Get Arvinas News Delivered to You Automatically

ARVN Media Mentions By Week

ARVN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARVN
News Sentiment
▼
0.12

0.35
▲
Average
Medical
News Sentiment

ARVN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARVN Articles
This Week
▼
6

2
▲
ARVN Articles
Average Week

Source

Source	Headline
	Analysts Set Arvinas, Inc. (NASDAQ:ARVN) PT at $68.44 americanbankingnews.com - March 23 at 6:44 AM
	Arvinas (NASDAQ:ARVN) Given New $77.00 Price Target at Citigroup americanbankingnews.com - March 21 at 2:30 AM
	Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 6.5% in February americanbankingnews.com - March 17 at 5:58 AM
	Arvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags finance.yahoo.com - February 24 at 7:11 AM
	A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN) finance.yahoo.com - February 24 at 7:11 AM
	Arvinas to Participate in Upcoming Investor Conferences finance.yahoo.com - February 6 at 7:58 PM
	Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock? finance.yahoo.com - January 11 at 12:33 PM
	Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 4 at 9:44 AM
	Investors in Arvinas (NASDAQ:ARVN) from a year ago are still down 57%, even after 5.4% gain this past week finance.yahoo.com - January 3 at 7:38 AM
	Arvinas, Inc. (ARVN) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - December 31 at 6:37 PM
	Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting finance.yahoo.com - November 22 at 5:41 PM
	SVB Securities Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN) markets.businessinsider.com - November 10 at 8:40 AM
	Arvinas to Present at Upcoming Conferences finance.yahoo.com - November 1 at 7:01 PM
	Why Arvinas (ARVN) Might Surprise This Earnings Season finance.yahoo.com - November 1 at 2:01 PM
	ARVN.N - Arvinas Inc \| Stock Price & Latest News \| Reuters reuters.com - October 10 at 8:31 AM
	Secretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors - Business Wire businesswire.com - October 4 at 5:02 PM
	Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs finance.yahoo.com - October 3 at 8:35 AM
	Arvinas Gives Back to Local Greater New Haven Community - GlobeNewswire globenewswire.com - September 30 at 10:12 AM
	Arvinas Gives Back to Local Greater New Haven Community finance.yahoo.com - September 30 at 10:12 AM
	Arvinas to Present at Bank of America Securities Precision Oncology Conference - GlobeNewswire globenewswire.com - September 26 at 8:11 AM
	Arvinas to Present at Bank of America Securities Precision Oncology Conference finance.yahoo.com - September 26 at 8:11 AM
	Pardes Biosciences (PRDS) Appoints Laurie Smaldone Alsup and John C. Pottage to its Board - StreetInsider.com streetinsider.com - September 14 at 10:25 AM
	Arvinas (NASDAQ:ARVN) – hC Bioscience Appoints Brad Margus to its Board of Directors - Benzinga benzinga.com - September 13 at 3:22 PM
	Arvinas (NASDAQ:ARVN) – Where Arvinas Stands With Analysts - Benzinga benzinga.com - September 9 at 11:31 PM
	ARVN stock initiated Overweight at Barclays on therapeutic platform (NASDAQ:ARVN) - Seeking Alpha seekingalpha.com - September 9 at 6:30 PM
	Arvinas (NASDAQ:ARVN) – Expert Ratings for Arvinas - Benzinga benzinga.com - September 9 at 6:30 PM
	Investors in Arvinas (NASDAQ:ARVN) have made a decent return of 80% over the past three years nasdaq.com - August 28 at 6:45 PM
	Investors in Arvinas (NASDAQ:ARVN) have made a decent return of 80% over the past three years - Nasdaq nasdaq.com - August 26 at 4:50 PM
	Arvinas Stock: Sports Unappealing Risk/Reward Profile (NASDAQ:ARVN) - Seeking Alpha seekingalpha.com - August 25 at 3:14 AM
	Arvinas's Return on Invested Capital Insights - Benzinga benzinga.com - August 22 at 11:19 AM
	Arvianas a buy at Piper Sandler following (failure of Sanofi breast cancer treatment - Seeking Alpha seekingalpha.com - August 19 at 5:57 PM
	Arvinas Announces Changes to its Board of Directors - GlobeNewswire globenewswire.com - August 18 at 4:26 PM
	Arvinas Announces Changes to its Board of Directors finance.yahoo.com - August 18 at 4:26 PM
	Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations - GlobeNewswire globenewswire.com - August 15 at 8:16 AM
	Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations finance.yahoo.com - August 15 at 8:16 AM
	8 Analysts Have This to Say About Arvinas markets.businessinsider.com - August 8 at 11:43 PM
	Arvinas GAAP EPS of $1.32 beats by $2.38, revenue of $31.3M beats by $7.59M (NASDAQ:ARVN) - Seeking Alpha seekingalpha.com - August 6 at 4:44 AM
	Recap: Arvinas Q2 Earnings - Benzinga benzinga.com - August 4 at 12:39 PM
	Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire globenewswire.com - August 4 at 7:38 AM
	Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - August 4 at 7:38 AM
	Arvinas Appoints John Northcott as Chief Commercial Officer - GlobeNewswire globenewswire.com - August 1 at 7:39 AM
	Arvinas Appoints John Northcott as Chief Commercial Officer benzinga.com - August 1 at 7:07 AM
	Arrival to Report Second Quarter 2022 Financial Results on August 11, 2022 - Yahoo Finance finance.yahoo.com - July 29 at 8:23 AM
	Those who invested in Arvinas (NASDAQ:ARVN) three years ago are up 94% finance.yahoo.com - July 27 at 10:13 AM
	Biotech Stocks Go Gangbusters As FOMO Drives A 3-Week, Double-Digit Run - Investor's Business Daily investors.com - July 6 at 2:48 PM
	Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar? - Nasdaq nasdaq.com - June 28 at 3:27 AM
	Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar? finance.yahoo.com - June 27 at 5:26 PM
	7 Analysts Have This to Say About Arvinas - Benzinga - Benzinga benzinga.com - June 22 at 6:23 AM
	Jefferies Initiates Coverage On Arvinas with Hold Rating, Announces Price Target of $42 - Benzinga - Benzinga benzinga.com - June 21 at 5:21 AM
	Arvinas Inc - Stock Analysis morningstar.com - June 17 at 11:19 PM

Get Arvinas News Delivered to You Automatically

This page (NASDAQ:ARVN) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arvinas - ARVN News Today

ARVN Media Mentions By Week

ARVN Media Sentiment

ARVN News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info